Effect of rituximab on heart involvement in systemic sclerosis
https://doi.org/10.14412/1995-4484-2018-709-715
Abstract
As of now, there has been a great body of data on the use of rituximab (RTM) in systemic sclerosis (SS), mainly on its positive effect on skin fibrosis and lung injury. However, information is still scarce about the effect of RTM on other organs and systems, namely the heart affected by SS.
Objective: to assess the time course of changes in the signs of heart involvement in SS patients one year after initiation of RTM therapy.
Subjects and methods. The paper gives data on changes in cardiac disorders in 71 patients with SS one year after the prescription of RTM.
Results and discussion. The rate of cardiac rhythm and conduction disorders and diastolic dysfunction was unchanged. At the same time, a significant increase in left ventricular ejection fraction (EF) and a reduction in the severity of dyspnea was achieved, which correlated with improved lung function (a significant rise in forced vital capacity). The results of treatment in three patients with predominant heart involvement associated with SS (coronary heart disease and hypertension were ruled out) were considered in detail. These patients displayed pronounced positive changes as increased EF, less severe cardiac arrhythmias, reduced chronic heart failure, better quality of life, as well as the synchronicity of lower disease activity, less skin induction, improved lung function, and stabilized pulmonary artery systolic pressure.
Conclusion. RTM in combination with traditional therapy can be considered as a potentially effective drug for the treatment of heart involvement in SS.
About the Authors
L. A. Garzanova
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow; 115522.
L. P. Ananyeva
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow; 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow; 115522.
O. A. Koneva
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow; 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow; 115522.
O. B. Ovsyannikova
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow; 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow; 115522.
References
1. Гусева НГ. Системная склеродермия и псевдосклеродермические синдромы. Москва: Медицина; 1993. 300 с. [Guseva NG. Sistemnaya sklerodermiya i psevdosklerodermicheskie sindromy [Systemic sclerosis and pseudoscleroderma syndromes]. Мoscow: Meditsina; 1993. 300 p. (In Russ.)].
2. Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii45-8. doi: 10.1093/rheumatology/kep110
3. Prasad M, Herman J, Gabriel SE, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015;12:168-76. doi: 10.1038/nrcardio.2014.206
4. Cannarile F, Valentini V, Mirabelli G, et al. Cardiovascular disease in systemic sclerosis. Ann Transl Med. 2015;1:8-19.
5. Parks JL, Taylor MH, Parks LP, Silver RM. Systemic Sclerosis and the Heart. Rheum Dis Clin N Am. 2014;40:87-102. doi: 10.1016/j.rdc.2013.10.007
6. Lee DC, Hinchcliff ME, Sarnari R, et al. Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis. J Scleroderm Relat Disord. 2018;3(2):159-69. doi: 10.1177/2397198318762888
7. Алекперов РТ, Черемухина ЕО, Новикова ДС, Ананьева ЛП. Нарушения ритма и проводимости сердца при системной склеродермии. Альманах клинической медицины. 2014;35:71-6 [Alekperov RT, Cheremukhina EO, Novikova DS, Anan'eva LP. Rhythm and conduction disorders of the heart in systemic scleroderma. Al'manakh Klinicheskoy Meditsiny. 2014;35:71-6 (In Russ.)].
8. Vacca A, Meune C, Gordon J, et al. Scleroderma Clinical Trial Consortium Cardiac Subcommittee. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology (Oxford). 2014 Jul;53(7):1172-7. doi: 10.1093/rheumatology/ket377
9. Au K, Singh MK, Bodukam V, et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum. 2011;63:2078-90. doi: 10.1002/art.30380
10. Magda SL, Mincu RI, Mihai CM, et al. Atherosclerosis in Systemic Sclerosis: a Modern Controversy. MAEDICA J Clin Med. 2015;10(3):248-56.
11. Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51(6):1017-26. doi: 10.1093/rheumatology/ker269
12. Sangesa S, Guerriera T, Launaya D, et al. Role of B cells in the pathogenesis of systemic sclerosis. Soc Nat Franc Med Int. 2016. doi: 10.1016/j.revmed.2016.02.016 0248-8663/
13. Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 suppl 71):S17-S22.
14. Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52-7. doi: 10.3899/jrheum.120778
15. Jordan S, Distler JH, Maurer B, et al; EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522
16. Jordan S, Maurer B, Michel B, Distler O. Performance of the new EULAR/ACR classification criteria for systemic sclerosis in clinical practice. Ann Rheum Dis. 2013;72 (Suppl 3):60. doi: 10.1136/annrheumdis-2013-eular.239
17. NYHA: Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol. 1995;26(5):1376-98. doi: 10.1016/0735-1097(95)00469-6
18. Valentini G, Della Rossa A, Bombardieri S, at al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592-8. doi: 10.1136/ard.60.6.592
19. Kahaleh MB, Sultany GL, Smith EA, et al. A modified scleroderma skin scoring method. Clin Exp Rheumatol. 1986;4(4):367-9.
20. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res. 1991;4:27-31. doi: 10.1002/art.1790040106
21. Bissell L-A, Anderson M, Burgess M, et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group management of cardiac disease in systemic sclerosis. Rheumatology. 2017;56:912-21. doi: 10.1093/rheumatology/kew488
22. Конева ОА, Ананьева ЛП, Овсянникова ОБ и др. Исследование эффективности и безопасности терапии микофенолата мофетилом у больных системной склеродермией. Научно-практическая ревматология. 2011;49(4):16-23 [Koneva OA, Ananyeva LP, Ovsyannikova OB, et al. Study of the efficiency and safety of mycophenolate mofetil therapy in patientswith systemic scleroderma. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(4):16-23 (In Russ.)]. doi: 10.14412/1995-4484-2011-56
23. Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Brit J Rheumatol. 1996;35:364-72. doi: 10.1093/rheumatology/35.4.364
24. Pieroni M, de Santis M, Zizzo G, et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: Potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum. 2014;43:526-35. doi: 10.1016/j.semarthrit.2013.07.006
25. Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578-83. doi: 10.1002/art.24249
26. Bosello S, de Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up openlabel trial. Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965
27. Smith V, van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193-7. doi: 10.1136/ard.2008.095463
28. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271-80. doi: 10.1093/rheumatology/kep093
29. Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015 Nov;14(11):1072-8. doi: 10.1016/j.autrev.2015.07.008
30. Bosello SL, de Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-36. doi: 10.1016/j.semarthrit.2014.09.002
31. Canete JD, Hernandez V, Sanmarti R. Safety profile of biological therapies for treating rheumatoid arthritis. Exp Opin Biol Ther. 2017. doi: 10.1080/14712598.2017.1346078
32. Van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol. 2015 Oct;42(10):1761-6. doi: 10.3899/jrheum.150051
Review
For citations:
Garzanova L.A., Ananyeva L.P., Koneva O.A., Ovsyannikova O.B. Effect of rituximab on heart involvement in systemic sclerosis. Rheumatology Science and Practice. 2018;56(6):709-715. (In Russ.) https://doi.org/10.14412/1995-4484-2018-709-715
Views:
1559
Email this article 